Advertisement
Grab your lab coat. Let's get started
Welcome!
Welcome!
Create an account below to get 6 C&EN articles per month, receive newsletters and more - all free.
It seems this is your first time logging in online. Please enter the following information to continue.
As an ACS member you automatically get access to this site. All we need is few more details to create your reading experience.
Not you? Sign in with a different account.
Not you? Sign in with a different account.
ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Business
Intrexon To Acquire Protein Drug Firm
by Ann M. Thayer
February 23, 2015
| A version of this story appeared in
Volume 93, Issue 8
Intrexon will pay $60 million in cash and stock to acquire the biopharmaceutical firm ActoGenix. Based in Ghent, Belgium, ActoGenix engineers food-grade Lactococcus lactis microbes it calls ActoBiotics to secrete therapeutic proteins in the oral and gastrointestinal tract. Now in clinical trials, the company’s AG013 delivers a peptide for preventing and controlling oral mucositis; AG014 secretes an anti-TNFα antibody to treat inflammatory bowel disease. Intrexon applies its synthetic biology capabilities to create cellular and gene therapies and to produce active ingredients.
The power is now in your (nitrile gloved) hands
Sign up for a free account to get more articles. Or choose the ACS option that’s right for you.
Already have an ACS ID? Log in
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on Twitter